Company facts
- Headquarters
- San Diego, California
- Most recent report
- 10-Q, filed Oct 29, 2026
- Incorporated
- Delaware
- Filings on record
- 1,000+ filings
- On EDGAR
- CIK 1093557
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 32
News 8 of 95
Prospectuses and Registrations 8 of 16
- S-8 Registration statement for an employee plan May 9, 2025
- S-3ASR Automatic shelf registration Feb 18, 2025
- 424B5 Prospectus supplement for an offering Nov 22, 2021
- S-3ASR Automatic shelf registration Nov 22, 2021
- S-8 POS Post-effective amendment to an employee plan registration Feb 10, 2021
- S-8 POS Post-effective amendment to an employee plan registration Feb 10, 2021
- S-8 POS Post-effective amendment to an employee plan registration Feb 10, 2021
- S-8 POS Post-effective amendment to an employee plan registration Feb 10, 2021
Proxies 8 of 19
- DEFA14A Extra proxy material Apr 15, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 15, 2026
- DEFA14A Extra proxy material May 2, 2025
- DEFA14A Extra proxy material Mar 27, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 27, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 22, 2024
- DEFA14A Extra proxy material Apr 6, 2023
- DEF 14A Proxy statement for a shareholder vote Apr 6, 2023
Ownership 8 of 820
- 4 Insider reported a trade Nov 3, 2026
- 4 Insider reported a trade Oct 28, 2026
- 144 Notice of a proposed sale of restricted stock Oct 27, 2026
- 4 Insider reported a trade Oct 19, 2026
- 144 Notice of a proposed sale of restricted stock Oct 15, 2026
- 4 Insider reported a trade Sep 30, 2026
- 144 Notice of a proposed sale of restricted stock Sep 28, 2026
- 4 Insider reported a trade Sep 16, 2026
Other 8 of 18
- SD Conflict minerals disclosure May 28, 2026
- ARS Annual report sent to shareholders Apr 15, 2026
- SD Conflict minerals disclosure May 29, 2025
- ARS Annual report sent to shareholders Mar 27, 2025
- SD Conflict minerals disclosure May 29, 2024
- ARS Annual report sent to shareholders Apr 22, 2024
- SD Conflict minerals disclosure May 31, 2023
- ARS Annual report sent to shareholders Apr 6, 2023
What to read: Sep 2026 10-Q
SECSift found 3 of 13 sections worth reading, with 1 positive, 7 notable, and 6 negative flags.
Financial Statements (Item 1)
Financial statements and notes with material balance-sheet swings, buyback, and litigation.PositiveNotableManagement's Discussion (Item 2)
MD&A with detailed financial results, cash flow, and liquidity analysis for Q3 2026.Notable- SG&A expense rose 13% to $375.6M in Q3 2026, driven by $20.7M more in advertising and marketing.
- Other income fell 93% to $7.5M in Q3 2026, mainly due to absence of an $82.5M prior-year gain on equity investments.
- Company plans to allocate at least 50% of operating cash flow (net of capex) to share repurchases over long-range plan.
- Cash and short-term securities fell to $1.82B as of Sep 2026, down $180.8M from $2.00B at Dec 2025.
Legal Proceedings (Item 1)
Multiple active securities and product class actions with ongoing appeals and motions.Negative- Securities class action dismissed with prejudice but now on appeal; appellant's brief due Nov 9, 2026.
- Second securities class action (Prime v. Dexcom) alleges false statements about G7 device accuracy; motion to dismiss fully briefed.
- Five derivative lawsuits filed, all stayed pending resolution of the securities class action appeal.
- Six product class actions allege G6/G7 devices were adulterated, misbranded, or failed to perform as advertised.
What changed: Sep 2026 vs. Jun 2026
About 4% of DXCM's Sep 2026 10-Q is new information. 14 paragraphs were added, 122 changed, and 22 removed. Below are the most important lines SECSift identified.
Changed
- Authorization date changed from May 2026 to October 2026.
- In the State Court Class Action, the stay was extended through at least February 26, 2027, and the next joint status report is due February 19, 2027. Previously the report was due August 19, 2026.
- Jereme Sylvain's title expanded to include Chief Operating Officer; prior was only CFO.
- Management participants changed to 'principal executive officer and principal financial officer' from 'President and Chief Executive Officer and our Chief Financial Officer'.
- Principal financial officer title changed to 'Chief Operating Officer and Chief Financial Officer' from 'Chief Financial Officer'.
Removed
- Prior filing had $250.0 million remaining under the old $750.0 million program, which was terminated.
- Prior filing mentioned termination of existing program with $250.0 million remaining; current filing omits this.
- Director Nicholas Augustinos adopted a plan for 8,089 shares on 6/10/2026, expiring 8/10/2027.
- EVP CFO Jereme Sylvain adopted a plan for 11,571 shares on 6/10/2026, expiring 6/10/2027.
- EVP Sadie Stern adopted a plan for 30,773 shares on 5/28/2026, expiring 8/26/2027.
- Prior filing gave repurchase data for three and six months ended June 30, 2026; current filing omits this.
Everything here comes from Dexcom Inc's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Oct 29, 2026, from the 10-Q for Sep 2026.